These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 35233862)
1. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma. Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862 [TBL] [Abstract][Full Text] [Related]
2. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas. de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754 [TBL] [Abstract][Full Text] [Related]
3. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma. Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932 [TBL] [Abstract][Full Text] [Related]
4. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial. Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434 [TBL] [Abstract][Full Text] [Related]
5. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912 [TBL] [Abstract][Full Text] [Related]
6. Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review. Sidibe I; Tensaouti F; Roques M; Cohen-Jonathan-Moyal E; Laprie A Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203493 [TBL] [Abstract][Full Text] [Related]
7. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM. Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308 [TBL] [Abstract][Full Text] [Related]
8. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis. Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959 [TBL] [Abstract][Full Text] [Related]
9. Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients. Yoo RE; Choi SH Magn Reson Med Sci; 2016; 15(2):165-77. PubMed ID: 26726012 [TBL] [Abstract][Full Text] [Related]
10. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma. Li Y; Ma Y; Wu Z; Xie R; Zeng F; Cai H; Lui S; Song B; Chen L; Wu M Front Immunol; 2021; 12():790674. PubMed ID: 34899760 [TBL] [Abstract][Full Text] [Related]
11. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy. Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633 [TBL] [Abstract][Full Text] [Related]
12. Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from T Sun YZ; Yan LF; Han Y; Nan HY; Xiao G; Tian Q; Pu WH; Li ZY; Wei XC; Wang W; Cui GB BMC Med Imaging; 2021 Feb; 21(1):17. PubMed ID: 33535988 [TBL] [Abstract][Full Text] [Related]
13. Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. Akbari H; Rathore S; Bakas S; Nasrallah MP; Shukla G; Mamourian E; Rozycki M; Bagley SJ; Rudie JD; Flanders AE; Dicker AP; Desai AS; O'Rourke DM; Brem S; Lustig R; Mohan S; Wolf RL; Bilello M; Martinez-Lage M; Davatzikos C Cancer; 2020 Jun; 126(11):2625-2636. PubMed ID: 32129893 [TBL] [Abstract][Full Text] [Related]
14. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. Shiroishi MS; Boxerman JL; Pope WB Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321 [TBL] [Abstract][Full Text] [Related]
15. Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review. Bonm AV; Ritterbusch R; Throckmorton P; Graber JJ J Neuroimaging; 2020 Mar; 30(2):139-145. PubMed ID: 31925884 [TBL] [Abstract][Full Text] [Related]
16. Imaging and Liquid Biopsy for Distinguishing True Progression From Pseudoprogression in Gliomas, Current Advances and Challenges. Li K; Zhu Q; Yang J; Zheng Y; Du S; Song M; Peng Q; Yang R; Liu Y; Qi L Acad Radiol; 2024 Aug; 31(8):3366-3383. PubMed ID: 38614827 [TBL] [Abstract][Full Text] [Related]
17. Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation. Hagiwara A; Schlossman J; Shabani S; Raymond C; Tatekawa H; Abrey LE; Garcia J; Chinot O; Saran F; Nishikawa R; Henriksson R; Mason WP; Wick W; Cloughesy TF; Ellingson BM J Neurooncol; 2022 Sep; 159(3):509-518. PubMed ID: 35842871 [TBL] [Abstract][Full Text] [Related]
18. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma. Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710 [TBL] [Abstract][Full Text] [Related]
19. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers. Le Fèvre C; Constans JM; Chambrelant I; Antoni D; Bund C; Leroy-Freschini B; Schott R; Cebula H; Noël G Crit Rev Oncol Hematol; 2021 Mar; 159():103230. PubMed ID: 33515701 [TBL] [Abstract][Full Text] [Related]
20. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]